Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

· seekingalpha.com

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients August 10, 2026 8:00 AM EDTCompany...

Presentation

Good day, and welcome to the Tenax Therapeutics Phase 3 LEVEL Topline Results Conference Call. [Operator Instructions] Please note this event is b...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI